These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36798486)

  • 1. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
    Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
    Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
    Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
    Filler G; Tremblay O; Chen E; Huang SSH; Stein R
    Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
    Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
    Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
    Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study.
    Mindler GT; Stauffer A; Kranzl A; Penzkofer S; Ganger R; Radler C; Haeusler G; Raimann A
    Front Endocrinol (Lausanne); 2022; 13():866170. PubMed ID: 35399930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
    Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
    Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
    Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
    Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study.
    Portale AA; Ward L; Dahir K; Florenzano P; Ing SW; Jan de Beur SM; Martin RM; Meza-Martinez AI; Paloian N; Ashraf A; Dixon BP; Khan A; Langman C; Chen A; Wang C; Roberts MS; Tandon PK; Bedrosian C; Imel EA
    J Bone Miner Res; 2024 Sep; 39(10):1493-1502. PubMed ID: 39151033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect and safety of Burosumab in the treatment of 4 children with X-linked hypophosphatemia].
    Wei LY; Sun Y; Gong CX; Cao BY
    Zhonghua Er Ke Za Zhi; 2024 Jul; 62(7):681-685. PubMed ID: 38955688
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
    Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review.
    Dodamani MH; Kumar SC; Bhattacharjee S; Barnabas R; Kumar S; Ranjan Lila A; Samad Memon S; Karlekar M; A Patil V; R Bandgar T
    Arch Endocrinol Metab; 2024 May; 68():e230242. PubMed ID: 38788147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.